Key result
Losartan was associated with a more favorable 2-year evolution of absolute LV global longitudinal strain.
Why the study?
Does losartan improve left ventricular remodeling and function (including global longitudinal strain) in hypertensive patients with mild-to-moderate aortic stenosis compared to no renin-angiotensin system inhibition?
Cohort (n=36)
Does losartan improve left ventricular remodeling and function (including global longitudinal strain) in hypertensive patients with mild-to-moderate aortic stenosis compared to no renin-angiotensin system inhibition?
In hypertensive patients with mild-to-moderate aortic stenosis, losartan use was associated with better preservation of left ventricular global longitudinal strain over two years, though larger randomized trials are needed.
Answers are grounded in this paper and cite their sources.
Losartan may preserve LV strain in hypertensive aortic stenosis; hypothesis-generating and requires randomized trials before practice change.
Hypertension is highly prevalent in patients with aortic stenosis (AS) and contributes to adverse left ventricular (LV) remodeling. We investigated the association between losartan treatment and LV remodeling and function in hypertensive patients with mild-to-moderate AS. In this prospective comparative cohort study, 18 AS patients receiving losartan were individually matched with 18 controls from the PROGRESSA cohort not receiving renin-angiotensin system inhibitors. Patients underwent echocardiographic assessment at baseline and two years. Between-group changes were compared within matched pairs, with baseline-adjusted sensitivity analyses. All losartan-treated patients completed follow-up without permanent treatment discontinuation or treatment-related serious adverse events. Systolic blood pressure decreased significantly within the losartan group, but the between-group difference in blood pressure changes was not significant (p = 0.17). Losartan was associated with a more favorable evolution of absolute global longitudinal strain (GLS), which persisted after baseline adjustment (adjusted between-group difference: +2.34%; 95% confidence interval 0.18-4.49; p = 0.04). Although LV end-diastolic diameter and relative wall thickness showed significant differences in unadjusted longitudinal analyses, these differences were no longer significant after baseline adjustment (p = 0.40 and p = 0.30, respectively). No significant between-group differences were observed in LV ejection fraction. In this small, non-randomized prospective study of hypertensive patients with mild-to-moderate AS, losartan treatment was associated with a more favorable evolution of LV GLS over two years. Associations with LV remodeling were not significant after baseline adjustment. These exploratory findings do not establish causality or treatment safety and warrant confirmation in larger, adequately powered randomized controlled trials.
No takes yet. Share an insight, caveat, or question.
Abdoun et al. (2026) conducted a cohort in Hypertension with mild-to-moderate aortic stenosis (n=36). Losartan vs. Matched controls from the PROGRESSA cohort not receiving renin-angiotensin system inhibitors was evaluated on Left ventricular absolute global longitudinal strain (GLS), function, and remodeling at 2 years (MD 2.34, 95% CI 0.18-4.49, p=0.04). Losartan was associated with a more favorable 2-year evolution of absolute LV global longitudinal strain.
Synapse has enriched 10 related papers. Consider them for comparative context: